WNC · Wabash National Corp. · Stock research

Current Thesis

Wabash is the only public U.S. pure-play trailer OEM, and the stock roughly doubled off its $6.63 52-week low (finviz) to a $14.32 high on a policy moat that arrived ahead of the fundamentals: preliminary countervailing duties of 82.3–128.7% and an affirmative preliminary antidumping finding on Chinese van-type trailers (Federal Register 2026-06-05), followed by a DA Davidson upgrade to Buy with the target lifted $8.50→$20 (2026-06-18). The leg an investor buys is a tariff-protected domestic OEM at a cyclical trough, with the 2026-08-24 final China determination as the structural catalyst. Two developments have since complicated a fresh entry near ~$12.36: the company priced a $130M 4.00% convertible note due 2032 (2026-07-16, conversion ~$16.75), which resolved the balance-sheet question into a dilutive raise rather than organic cash, and a loss-making Q2 print lands 2026-07-29 before the open — a binary directly in the path. The pre-catalyst asymmetry that existed in mid-June has largely been spent.

Bullish and bearish views on Wabash National Corp.

The model's bull view on Wabash National Corp. (WNC), in brief: Policy moat: preliminary countervailing duties of 82.3–128.7% plus an affirmative preliminary antidumping finding on Chinese van-type trailers (Federal Register 2026-06-05); the China final is aligned for 2026-08-24 and would reprice domestic build economics against imports. The bear view: The dilution event confirmed the fear: the $130M 4.00% convertible due 2032 priced 2026-07-16 at a ~$16.75 conversion price; shares fell ~14% after-hours on the 2026-07-14 announcement. Both cases follow in full.

Bull Case

• Policy moat: preliminary countervailing duties of 82.3–128.7% plus an affirmative preliminary antidumping finding on Chinese van-type trailers (Federal Register 2026-06-05); the China final is aligned for 2026-08-24 and would reprice domestic build economics against imports. Wabash is a petitioner via the American Trailer Manufacturers Coalition.
• Sell-side inflection: DA Davidson upgrade to Buy, PT $8.50→$20 (2026-06-18), citing management's 2027 replacement-demand framework; the stock gapped +16.4% to $10.80 that session and ran to $14.32.
• Backlog turned up: total backlog $837M in Q1 2026, +19% / +$132M q/q (reported ~2026-05-01), which management framed as a record first quarter — the first order-book build after the downturn.
• Sequential re-acceleration guided: Q2 revenue guide $380–400M against the $303.2M Q1 base (~+25–32% q/q), with the adjusted loss narrowing to −$0.40/−$0.60 from −$1.17.
• Operating leverage: build rates near 15-year lows leave heavy fixed-cost absorption to recover; consensus models a swing toward ~+$1.57 EPS next year (finviz) from −$1.59 ttm.
• Liquidity secured: the $130M convertible (upsized from $100M, plus a $20M option) closed ~2026-07-20, taking the near-term funding question off the table ahead of the ruling.
• Tail risk quantified: the $462M Sept-2024 Missouri verdict was cut to a $119.5M judgment (2025-03-20) and settled Oct 2025 for an ~$30M company contribution — no longer an existential overhang.

Bear Case

• The dilution event confirmed the fear: the $130M 4.00% convertible due 2032 priced 2026-07-16 at a ~$16.75 conversion price; shares fell ~14% after-hours on the 2026-07-14 announcement. The balance-sheet watch resolved to a capital raise, not organic cash generation.
• Still bleeding cash: Q1 2026 posted a −$11M consolidated gross loss (−3.5% of sales) and −$1.17 EPS; Q2 guidance keeps operating margin near −5%, and the Street doesn't model profitability before 2027.
• Solvency overhang persists: enterprise value has run above equity value, net debt has exceeded market cap, and the raise layers on ~$130M of convertible debt even as it buys time.
• Pre-catalyst edge spent: the 2026-06-18 DA Davidson upgrade is the only active Buy and it landed after the double; the asymmetry that existed in mid-June is gone.
• Ruling risk: the 82–129% duties are preliminary; the 2026-08-24 China final can be reduced, and importers front-loaded inventory ahead of it, muffling near-term order pull-through. Mexico's parallel duties are only 1.9–1.95% (final 2026-10-13), so the moat is China-specific.
• Binary in the path: Q1 results triggered an ~11.6% next-day drop (2026-05-02); the 2026-07-29 pre-market print is another loss with the same gap risk.

Setup & Price Structure

• Price ~$12.36 (late July), roughly 14% below the $14.32 52-week high and near double the $6.63 low; GF Value pegged ~$13.59, with $12.90 printed on the 2026-07-10 up-day before the convertible headline.
• The 2026-06-18 upgrade gap to $10.80 is the structural reference; the stock ran to $14.32, then gave back into the low-$12s as the convertible offering hit and settled around ~$12.36 after the after-hours air-pocket.
• The mid-June advance cleared a 10/50-day golden cross with RSI stretched into the low-70s at the high; the pullback has worked off some overbought condition without carving a fresh higher-low base.
• The tape sits between the $10.80 catalyst gap (support / invalidation) and the $14.32 high (resistance), consolidating into two binaries — a cooled chase zone rather than a clean breakout-retest.
• Entry discipline: a fresh position here carries earnings gap risk in ~2 trading days plus the fresh dilution overhang; better risk/reward comes from a post-print base or a confirmed hold of $10.80 after the 2026-08-24 ruling.

Catalyst Calendar (next 30 days)

• 2026-07-29 (confirmed): Q2 2026 earnings before market open, conference call 12:00pm ET. Guide is a loss (adj EPS −$0.40/−$0.60, op margin ~−5%); watch backlog versus the $837M Q1 mark and any duty-driven order commentary. Binary event.
• 2026-08-01: first coupon reference date for the 4.00% notes (interest payable Feb 1 / Aug 1). Minor.
• 2026-08-24 (scheduled, just beyond 30d but decisive): final China AD/CVD determination — the structural catalyst. Preliminary CVD 82.3–128.7% plus affirmative AD; an in-band final ratifies the moat, a cut voids much of the re-rating.

Elapsed catalysts

• ~2026-07-20 (closed): $130M convertible settlement — dilution mechanics, use of proceeds, and net-debt trajectory feed the balance-sheet read into the print. (passed 9d ago)

What Would Change Our Mind

• A weekly close below $10.80 fills the June-18 countervailing-duty gap and voids the entire re-rating — the line that turns the policy-moat story into a failed breakout.
• Secondary: the 2026-08-24 final China determination landing materially below the 82–129% preliminary band, which removes the structural pillar of the thesis.
• Secondary: Q2 backlog reversing under ~$705M on the 2026-07-29 print, signalling the order build was a one-quarter blip rather than a cycle turn.
• Confirmation the other way (would raise conviction): a post-print hold above the low-$12s with backlog extending past $837M, then an in-band final ruling — that sequence supports pressing a clean higher-low base instead of chasing the extended tape.

Correlation Notes

• Trailer OEMs lag the freight cycle; carriers (KNX/WERN/SNDR) and truck OEM PCAR inflect first, so WNC strength is not confirmed without freight-complex leadership. Sector momentum ≠ WNC momentum.
• The name trades on tariff-trade-protection headlines as much as freight fundamentals; the duty docket (China final 2026-08-24, Mexico 2026-10-13) is a bigger near-term driver than DAT spot van rates.
• Only U.S.-listed pure-play trailer OEM, so there is no clean domestic peer to cross-confirm; read-through comes from freight carriers, dry-van rate data, and Class 8 build rates (ACT Research).
• Small-cap, high-beta, cyclical-industrials basket; moves with risk-on rotation and can gap on thin liquidity around the print.